Study wrapper · #1260
Dual-transporter-targeted oral nanomicelles of semaglutide enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
Editor's note
A well-characterised drug-delivery paper: particle size, incorporation efficiency and the transporter mechanism (ASBT and GLUT2, plus endocytosis) are all documented, and the oral-to-subcutaneous comparison is run in the same model. The ceiling is that relative oral bioavailability was still only 4.62 percent, and everything here is Caco-2 monolayers and high-fat-diet mice — no human data. Doses in mg/kg in mice do not map onto human dosing. Read it as formulation progress, not as evidence about any product available now.
Plain-language abstract
Researchers built a nanoparticle carrier designed to help semaglutide survive the gut and cross the intestinal wall, aiming at an oral version of the injected drug. In cell models the carrier raised permeability roughly 29-fold, and in obese mice a daily 5 mg/kg oral dose lowered body weight by about 30 percent and fasting glucose by about 66 percent. At the highest oral dose the effects approached those of injected semaglutide in the same experiment.